117 related articles for article (PubMed ID: 33446148)
1. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain.
Martínez-Lago N; Fernández-Montes A; Covela M; Brozos EM; De la Cámara J; Méndez Méndez JC; Jorge-Fernández M; Cousillas Castiñeiras A; Reboredo C; Arias Ron D; Pellón Augusto ML; González Villarroel P; Graña B; Salgado Fernández M; Carral Maseda A; Vázquez Rivera F; Candamio Folgar S; Reboredo López M;
BMC Cancer; 2021 Jan; 21(1):64. PubMed ID: 33446148
[TBL] [Abstract][Full Text] [Related]
2. Impact of Metastasectomy in the Multimodality Approach for
Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A
Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173
[TBL] [Abstract][Full Text] [Related]
3. Treatment of patients with BRAF
Germani MM; Vetere G; Santamaria F; Intini R; Ghelardi F; Bensi M; Boccaccino A; Minelli A; Carullo M; Ciracì P; Passardi A; Santucci S; Giampieri R; Persano M; Fenocchio E; Puccini A; Lonardi S; Pietrantonio F; Salvatore L; Cremolini C
ESMO Open; 2024 Apr; 9(4):102996. PubMed ID: 38613911
[TBL] [Abstract][Full Text] [Related]
4. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments.
Ros J; Matito J; Villacampa G; Comas R; Garcia A; Martini G; Baraibar I; Saoudi N; Salvà F; Martin Á; Antista M; Toledo R; Martinelli E; Pietrantonio F; Boccaccino A; Cremolini C; Dientsmann R; Tabernero J; Vivancos A; Elez E
Ann Oncol; 2023 Jun; 34(6):543-552. PubMed ID: 36921693
[TBL] [Abstract][Full Text] [Related]
5. Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China.
Xu Y; Wang G; Zheng X; Chang W; Fu J; Zhang T; Lin Q; Lv Y; Zhu Z; Tang W; Xu J
Eur J Surg Oncol; 2023 Nov; 49(11):106981. PubMed ID: 37455182
[TBL] [Abstract][Full Text] [Related]
6. The BEETS (JACCRO CC-18) trial: an observational and translational study of
Inagaki C; Matoba R; Yuki S; Shiozawa M; Tsuji A; Inoue E; Muro K; Ichikawa W; Fujii M; Sunakawa Y
Future Oncol; 2023 Jun; 19(17):1165-1174. PubMed ID: 37458152
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of
de la Fouchardière C; Cohen R; Malka D; Guimbaud R; Bourien H; Lièvre A; Cacheux W; Artru P; François E; Gilabert M; Samalin-Scalzi E; Zaanan A; Hautefeuille V; Rousseau B; Senellart H; Coriat R; Flippot R; Desseigne F; Lardy-Cleaud A; Tougeron D
Oncologist; 2019 Dec; 24(12):e1331-e1340. PubMed ID: 31152084
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab.
Passardi A; Azzali I; Bittoni A; Marisi G; Rebuzzi F; Molinari C; Bartolini G; Matteucci L; Sullo FG; Debonis SA; Gallio C; Monti M; Valgiusti M; Muratore M; Rapposelli IG; Ulivi P; Frassineti GL
Ther Adv Med Oncol; 2023; 15():17588359231212184. PubMed ID: 38107830
[TBL] [Abstract][Full Text] [Related]
9. BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database.
Cohen R; Liu H; Fiskum J; Adams R; Chibaudel B; Maughan TS; Van Cutsem E; Venook A; Douillard JY; Heinemann V; Ja Punt C; Falcone A; Bokemeyer C; Kaplan R; Lenz HJ; Koopman M; Yoshino T; Zalcberg J; Grothey A; de Gramont A; Shi Q; André T
J Natl Cancer Inst; 2021 Oct; 113(10):1386-1395. PubMed ID: 33734401
[TBL] [Abstract][Full Text] [Related]
10. Impact of encorafenib on survival of patients with BRAF
Zurloh M; Goetz M; Herold T; Treckmann J; Markus P; Schumacher B; Albers D; Rink A; Rosery V; Zaun G; Kostbade K; Pogorzelski M; Ting S; Schmidt H; Stiens R; Wiesweg M; Schuler M; Kasper S; Virchow I
J Cancer Res Clin Oncol; 2023 Nov; 149(14):12903-12912. PubMed ID: 37466791
[TBL] [Abstract][Full Text] [Related]
11. Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts.
Osterlund E; Ristimäki A; Mäkinen MJ; Kytölä S; Kononen J; Pfeiffer P; Soveri LM; Keinänen M; Sorbye H; Nunes L; Salminen T; Nieminen L; Uutela A; Halonen P; Ålgars A; Sundström J; Kallio R; Ristamäki R; Lamminmäki A; Stedt H; Heervä E; Kuopio T; Sjöblom T; Isoniemi H; Glimelius B; Osterlund P
Int J Cancer; 2024 Feb; 154(3):488-503. PubMed ID: 37724848
[TBL] [Abstract][Full Text] [Related]
12. BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.
Caputo F; Santini C; Bardasi C; Cerma K; Casadei-Gardini A; Spallanzani A; Andrikou K; Cascinu S; Gelsomino F
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661924
[TBL] [Abstract][Full Text] [Related]
13. Reduction of derived neutrophil-to-lymphocyte ratio after four weeks predicts the outcome of patients receiving second-line chemotherapy for metastatic colorectal cancer.
Colloca GA; Venturino A; Guarneri D
Cancer Immunol Immunother; 2021 Apr; 70(4):1115-1125. PubMed ID: 33123753
[TBL] [Abstract][Full Text] [Related]
14. Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer.
Johnson B; Kopetz S
Target Oncol; 2020 Oct; 15(5):567-577. PubMed ID: 32889679
[TBL] [Abstract][Full Text] [Related]
15. Clinical research progress on BRAF V600E-mutant advanced colorectal cancer.
Zeng C; Wang M; Xie S; Wang N; Wang Z; Yi D; Kong F; Chen L
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16111-16121. PubMed ID: 37639010
[TBL] [Abstract][Full Text] [Related]
16. Key Prognostic Factors Create a Composite Risk Score to Stratify Patients into High- and Low-Treatment Benefit Groups: A Multicenter, Retrospective Data Analysis of 84 Metastatic Colorectal Cancer Patients Treated with Regorafenib as Part of the CORRECT and CONSIGN Trials.
Zöhrlaut LK; Karthaus M; Vehling-Kaiser U; von Kunhardt L; Stintzing S; Heinemann V; von Einem JC
Oncol Res Treat; 2023; 46(9):348-361. PubMed ID: 37607525
[TBL] [Abstract][Full Text] [Related]
17. Effect of age on the effectiveness of the first-line standard of care treatment in patients with metastatic colorectal cancer: systematic review of observational studies.
Dagher M; Sabidó M; Zöllner Y
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2105-2114. PubMed ID: 31201484
[TBL] [Abstract][Full Text] [Related]
18. Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients.
Samalin E; Mazard T; Assenat E; Rouyer M; de la Fouchardière C; Guimbaud R; Smith D; Portales F; Ychou M; Adenis A; Fiess C; Lopez-Crapez E; Thezenas S
Dig Liver Dis; 2024 Jan; ():. PubMed ID: 38233313
[TBL] [Abstract][Full Text] [Related]
19. The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting.
Kopecký J; Pásek M; Lakomý R; Melichar B; Mrazová I; Kubeček O; Arenbergerová M; Lemstrová R; Švancarová A; Tretera V; Hlodáková A; Žváčková K
Cancer Med; 2024 Mar; 13(5):e6982. PubMed ID: 38491825
[TBL] [Abstract][Full Text] [Related]
20. Predictive Impact of
Moretto R; Germani MM; Ros J; Daniel F; Ghelardi F; Vetere G; Giordano M; Toledo RA; Bergamo F; Randon G; Elez E; Lonardi S; Pietrantonio F; Vignali P; Rossini D; Matito J; Ugolini C; Fontanini G; Masi G; Cremolini C
JCO Precis Oncol; 2023 Sep; 7():e2300255. PubMed ID: 37797285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]